Long-term expression and repeated administration of AAV type 1, 2 and 5 vectors in skeletal muscle of immunocompetent adult mice.
about
Perspectives of stem cell therapy in Duchenne muscular dystrophyPredictors of hepatitis B cure using gene therapy to deliver DNA cleavage enzymes: a mathematical modeling approachRecombinant adeno-associated viral (rAAV) vectors mediate efficient gene transduction in cultured neonatal and adult microgliaDevelopment of Patient-specific AAV Vectors After Neutralizing Antibody Selection for Enhanced Muscle Gene TransferDHPR alpha1S subunit controls skeletal muscle mass and morphogenesis.Protein-anchoring strategy for delivering acetylcholinesterase to the neuromuscular junction.Designer gene delivery vectors: molecular engineering and evolution of adeno-associated viral vectors for enhanced gene transferA comparison of synthetic oligodeoxynucleotides, DNA fragments and AAV-1 for targeted episomal and chromosomal gene repairActin scaffolding by clathrin heavy chain is required for skeletal muscle sarcomere organization.AAV's anatomy: roadmap for optimizing vectors for translational successComparative study of anti-hepatitis B virus RNA interference by double-stranded adeno-associated virus serotypes 7, 8, and 9.Expression of neprilysin in skeletal muscle reduces amyloid burden in a transgenic mouse model of Alzheimer diseaseEstablishment of an AAV reverse infection-based array.Subretinal delivery of adeno-associated virus serotype 2 results in minimal immune responses that allow repeat vector administration in immunocompetent mice.Comparison of adeno-associated virus pseudotype 1, 2, and 8 vectors administered by intramuscular injection in the treatment of murine phenylketonuriaTranslating Sleeping Beauty transposition into cellular therapies: victories and challenges.Gene therapy for muscular dystrophies: progress and challengesTransduction of the inner mouse retina using AAVrh8 and AAVrh10 via intravitreal injectionImpaired adaptive response to mechanical overloading in dystrophic skeletal muscleGene replacement therapies for duchenne muscular dystrophy using adeno-associated viral vectors.Advances in gene therapy for movement disorders.A dystrophic muscle broadens the contribution and activation of immune cells reacting to rAAV gene transfer.Adeno-associated viral vector serotype 5 poorly transduces liver in rat modelsAAV-mediated in vivo knockdown of luciferase using combinatorial RNAi and U1i.Specific binding of collagen Q to the neuromuscular junction is exploited to cure congenital myasthenia and to explore bases of myasthenia gravis.Immune Responses to rAAV6: The Influence of Canine Parvovirus Vaccination and Neonatal Administration of Viral VectorA 10 patient case report on the impact of plasmapheresis upon neutralizing factors against adeno-associated virus (AAV) types 1, 2, 6, and 8.MyD88 signaling in B cells regulates the production of Th1-dependent antibodies to AAVSingle amino acid modification of adeno-associated virus capsid changes transduction and humoral immune profiles.New vectors and strategies for cardiovascular gene therapy.Lack of repeat transduction by recombinant adeno-associated virus type 5/5 vectors in the mouse airwayProinsulin slows retinal degeneration and vision loss in the P23H rat model of retinitis pigmentosaViral-mediated expression of desmin mutants to create mouse models of myofibrillar myopathy.AAV-mediated gene transfer for retinal diseases.Serotype-specific Binding Properties and Nanoparticle Characteristics Contribute to the Immunogenicity of rAAV1 VectorsRobust Long-term Transduction of Common Marmoset Neuromuscular Tissue With rAAV1 and rAAV9.Priming with rAAV encoding RBD of SARS-CoV S protein and boosting with RBD-specific peptides for T cell epitopes elevated humoral and cellular immune responses against SARS-CoV infection.Immunity to adeno-associated virus vectors in animals and humans: a continued challenge.Effect of vascular endothelial growth factor gene therapy on post-traumatic peripheral nerve regeneration and denervation-related muscle atrophy.Reprogramming the Dynamin 2 mRNA by Spliceosome-mediated RNA Trans-splicing.
P2860
Q27013613-875FBAA6-6AB5-45AC-84A6-B1D681C65E93Q27324340-DE7C1809-AE3C-4AD6-BD96-7C69A8D5C737Q28386583-6AF22BEE-F520-406B-B0A3-720A91226ED0Q30152887-6DF619B1-2894-4F90-88FD-1B6E05D23569Q30493438-B467D6A2-BDC0-4750-A676-4A9BD5899616Q30519561-8B5D5FA6-392E-4960-8E09-7890749CD909Q33296224-684FD89E-16E9-474E-9689-F8DA2B6AC4A9Q33432320-85E7E53A-6D88-4C48-AC5C-C769CA46A3C3Q33601446-706B3EF7-A966-4A65-A046-347186D2F7E9Q33659389-031538D6-3644-4937-AB4D-9B4E8E063394Q33713259-83AD50CF-5076-4666-9C20-86A6A5504454Q33713881-EA4E9D0F-4404-46F2-8B8C-EDA3366D853EQ33728191-1195B7A3-6A0C-44BF-AC7D-2543711D3155Q33739804-65050D6B-7D08-4239-B19B-850E7284C3F1Q33832790-34E0CBBB-F4FA-4EE9-AF01-2DA4E456CF80Q34127579-73B63CAC-0629-4DEF-B032-E086331C3AC3Q34180144-CDC549A2-C865-4536-AAA7-7A85DD718FADQ34233343-AAAD0B1D-40EB-4FB6-8D5C-7E3897A9D7F0Q34237002-015C93B5-5301-4D3F-BFDD-BA706262DC01Q34566454-5391AC88-25A9-4261-9D83-8EF0EDA544B4Q34656049-8FE52F4D-DEC0-42C6-9B94-BE780A412260Q34814931-2BA68ED7-642A-4885-900D-588220DA1433Q35080025-F6F5C855-BA70-461B-861C-3EA5E10D073CQ35204876-364A269E-D067-464E-964C-D37536A7D62BQ35511648-2E8B6323-3CEF-41C3-AF03-401B067E5C80Q35513407-4044D0EF-FBD9-4D00-BF62-7F5FAA460F6AQ35568505-F066DC65-45B9-4735-8CDB-1C08A9399EC7Q36142477-9BAAF920-A11A-4815-B5A4-706ECB8833E1Q36171820-10A66D0C-0556-4C70-8A93-603862C9B102Q36174173-74573941-9A96-4367-9C64-D5EDC3ED9872Q36315561-C848335E-03AC-4664-8CB0-5605F2A1CA2BQ36469478-8785FD86-FAA7-412D-91F2-9894737CBDC8Q36690402-3C95AAE4-27EB-47B5-8E9E-B868D97409E2Q36708300-FCC1C942-9413-4B97-ACD2-69E5E56257EEQ36756695-702E8603-F91B-4C9D-99C5-22E38108B3F2Q36757156-D53714C8-1776-4CF3-BA4F-3141F0C6D12DQ37011150-B7DC2FD1-DE64-4157-AF26-7A1D259A3386Q37127246-BB2A7E9B-8EDD-4817-8E96-3514D53D8C94Q37226783-35F376B3-67DD-423F-8408-2D67F3CAE4FFQ37325074-8FDB9E06-CABC-4252-9899-A1142A005150
P2860
Long-term expression and repeated administration of AAV type 1, 2 and 5 vectors in skeletal muscle of immunocompetent adult mice.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
Long-term expression and repea ...... of immunocompetent adult mice.
@en
Long-term expression and repea ...... of immunocompetent adult mice.
@nl
type
label
Long-term expression and repea ...... of immunocompetent adult mice.
@en
Long-term expression and repea ...... of immunocompetent adult mice.
@nl
prefLabel
Long-term expression and repea ...... of immunocompetent adult mice.
@en
Long-term expression and repea ...... of immunocompetent adult mice.
@nl
P2093
P2860
P356
P1433
P1476
Long-term expression and repea ...... of immunocompetent adult mice.
@en
P2093
P2860
P2888
P304
P356
10.1038/SJ.GT.3302766
P577
2006-05-11T00:00:00Z
P5875
P6179
1030428417